Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Royal Bank of Canada

Analysts at Royal Bank of Canada initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) in a report issued on Friday, The Fly reports. The firm set an “outperform” rating and a $23.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would suggest a potential upside of 307.08% from the stock’s previous close.

MRNS has been the topic of several other research reports. StockNews.com raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, November 14th. Robert W. Baird dropped their target price on Marinus Pharmaceuticals from $32.00 to $24.00 and set an “outperform” rating on the stock in a report on Wednesday, November 9th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Marinus Pharmaceuticals in a report on Friday, January 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.63.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ MRNS opened at $5.65 on Friday. The company has a current ratio of 8.41, a quick ratio of 8.40 and a debt-to-equity ratio of 0.91. The stock has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $5.46. The company has a market cap of $210.16 million, a PE ratio of -12.28 and a beta of 1.10. Marinus Pharmaceuticals has a 12-month low of $3.46 and a 12-month high of $12.37.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.60). The business had revenue of $2.34 million for the quarter, compared to analyst estimates of $28.56 million. Marinus Pharmaceuticals had a negative return on equity of 244.60% and a negative net margin of 77.96%. On average, equities research analysts forecast that Marinus Pharmaceuticals will post -2.74 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MRNS. Quantbot Technologies LP bought a new position in shares of Marinus Pharmaceuticals in the first quarter valued at $40,000. Amalgamated Bank purchased a new position in Marinus Pharmaceuticals during the 1st quarter worth approximately $56,000. PDT Partners LLC purchased a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $63,000. Laurion Capital Management LP purchased a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $74,000. Finally, Price T Rowe Associates Inc. MD grew its position in Marinus Pharmaceuticals by 39.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 4,417 shares in the last quarter. Institutional investors own 86.88% of the company’s stock.

About Marinus Pharmaceuticals

(Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

See Also

The Fly logo

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.